Emcure Pharmaceuticals announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a robust 24.3% year-over-year growth in operating revenue, reaching INR 28,205 million. EBITDA saw a significant increase of 30.9%, while Profit After Tax (PAT) grew by 29.3%, reflecting strong operational performance and strategic execution.
Emcure Pharmaceuticals Q2 FY27 Financial Highlights
Emcure Pharmaceuticals has released its unaudited financial results for the second quarter and the first half of the financial year 2027. The company demonstrated strong performance across key financial metrics, underscoring its growth trajectory.
Revenue and Profitability Surge
For the quarter ended September 30, 2026 (Q2 FY27), Emcure Pharmaceuticals reported a substantial 24.3% increase in Operating Revenue compared to the same period last year, reaching INR 28,205 million. This growth was driven by both domestic and international business segments. The company’s EBITDA also saw a significant uplift of 30.9% year-over-year, indicating improved operational efficiency and profitability. The Profit After Tax (PAT) grew by 29.3%, with the PAT margin improving by 45 basis points to 11.5%.
Key Financial Metrics Breakdown
The presentation highlights key financial achievements for Q2 FY27:
- Revenue: INR 28,205 Mn (+24.3% YoY Growth)
- EBITDA: INR 5,748 Mn (+30.9% YoY Growth) with a margin of 20.4% (+103 bps YoY)
- PAT: INR 3,251 Mn (+29.3% YoY Growth) with a margin of 11.5% (+45 bps YoY)
Revenue Mix and Growth Drivers
The revenue for Q2 FY27 was composed of 41.0% Domestic revenue and 34.5% International revenue. Other regions like RoW, Europe, and Canada also contributed significantly to the overall growth. The company detailed segment-wise growth, with International business growing at 34.5% and Domestic business at 12.0% YoY.
Other Financial Data Points
Further insights from the presentation include:
- R&D expenditure as a percentage of revenue stood at 3.9% for H1FY27.
- Net Debt to TTM EBITDA ratio was maintained at 0.6x.
- Return on Capital Employed (RoCE) was reported at 24.9% as of September 30, 2026.
- Capital Expenditure (CAPEX) for H1FY27 was INR 2,877 Mn.
Business Performance Overview
Emcure Pharmaceuticals also provided updates on its domestic and international business performance. The domestic business saw sustained double-digit YoY growth, led by women’s health, cardio-metabolics, and CNS segments. Key brands like Orofer XT, Rosuvas EZ, and Tenectase showed strong growth. The international business also performed well across Europe, Canada, and the Rest of the World (RoW) markets, supported by new product launches and market share gains.
The company indicated that the presentation on its unaudited financial results is available on its website, www.emcure.com.
Source: BSE
